VEGFR tyrosine kinase inhibitor II (VRI) induced vascular insufficiency in zebrafish as a model for studying vascular toxicity and vascular preservation

Toxicology and Applied Pharmacology

Volumn 280, Issue 3, 2014, Pages 408-420

  Li, Shang ^a   Dang, Yuan Ye ^a   Oi Lam Che, Ginny ^a   Kwan, Yiu Wa ^b   Chan, Shun Wan ^c   Leung, George Pak Heng ^d   Lee, Simon Ming Yuen ^a   Hoi, Maggie Pui Man ^a  

^a UNIVERSITY OF MACAU   (Macao)

^b Prince of Wales Hospital   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular protective agents; Cardiovascular toxicity; Vascular insufficiency; Zebrafish model

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR II; UNCLASSIFIED DRUG; 7,3'-DIHYDROXY-4'-METHOXYISOFLAVONE; ISOFLAVONE DERIVATIVE; RNA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MORPHOGENESIS; NONHUMAN; ORGAN PRESERVATION; UMBILICAL VEIN ENDOTHELIAL CELL; ZEBRA FISH; ANIMAL; CHEMISTRY; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOLECULAR DYNAMICS; NICK END LABELING; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOPTOSIS; CELL SURVIVAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IN SITU NICK-END LABELING; ISOFLAVONES; MICROSCOPY, FLUORESCENCE; MOLECULAR DYNAMICS SIMULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; ZEBRAFISH;

EID: 84908394179     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.09.005     Document Type: Article

References (67)

1. Arnold S.F., Obourn J.D., Jaffe H., Notides A.C. Serine-167 is the major estradiol-induced phosphorylation site on the human estrogen-receptor. Mol. Endocrinol. 1994, 8:1208-1214.
2. Bahary N., Goishi K., Stuckenholz C., Weber G., Leblanc J., Schafer C.A., Berman S.S., Klagsbrun M., Zon L.I. Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. Blood 2007, 110:3627-3636.
3. Belloni D., Veschini L., Foglieni C., Dell'Antonio G., Caligaris-Cappio F., Ferrarini M., Ferrero E. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp. Cell Res. 2010, 316:1010-1018.
4. Bussolati B., Grange C., Camussi G. Tumor exploits alternative strategies to achieve vascularization. FASEB J. 2011, 25:2874-2882.
5. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha - a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276:9817-9824.
6. Ceresoli G.L., Zucali P.A. Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opin. Investig. Drugs 2012, 21:833-844.
7. Chan J., Bayliss P.E., Wood J.M., Roberts T.M. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell 2002, 1:257-267.
8. Chen J., Liu L., Hou R., Shao Z., Wu Y., Chen X., Zhou L. Calycosin promotes proliferation of estrogen receptor-positive cells via estrogen receptors and ERK1/2 activation in vitro and in vivo. Cancer Lett. 2011, 308:144-151.
9. Chen J., Hou R., Zhang X., Ye Y., Wang Y., Tian J. Calycosin suppresses breast cancer cell growth via ERbeta-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One 2014, 9:e91245.
10. Covassin L.D., Villefranc J.A., Kacergis M.C., Weinstein B.M., Lawson N.D. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6554-6559.
11. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
12. des Guetz G., Uzzan B., Chouahnia K., Morere J.F. Cardiovascular toxicity of anti-angiogenic drugs. Target. Oncol. 2011, 6:197-202.
13. el Filali M., van der Velden P.A., Luyten G.P.M., Jager M.J. Anti-angiogenic therapy in uveal melanoma. Dev. Ophthalmol. 2012, 49:117-136.
14. Eremina V., Quaggin S.E. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin. Nephrol. 2010, 30:582-590.
15. Eskens F.A., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 2006, 42:3127-3139.
16. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega A., Massimini G., Armand J.P., Scigalla P., Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 2006, 24:25-35.
17. Favaro E., Granata R., Miceli I., Baragli A., Settanni F., Cavallo Perin P., Ghigo E., Camussi G., Zanone M.M. The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 2012, 55:1058-1070.
18. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
19. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
20. Furet P., Bold G., Hofmann F., Manley P., Meyer T., Altmann K.H. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg. Med. Chem. Lett. 2003, 13:2967-2971.
21. Ganapathi A.M., Westmoreland T., Tyler D., Mantyh C.R. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. J. Am. Coll. Surg. 2012, 214:582-588. (discussion 588-590).
22. Habeck H., Odenthal J., Walderich B., Maischein H., Schulte-Merker S. Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr. Biol. 2002, 12:1405-1412.
23. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
24. Horsley L., Marti K., Jayson G.C. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin. Drug Metab. 2012, 8:283-293.
25. Isogai S., Lawson N.D., Torrealday S., Horiguchi M., Weinstein B.M. Angiogenic network formation in the developing vertebrate trunk. Development (Cambridge, England) 2003, 130:5281-5290.
26. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res. 2009, 102:19-65.
27. Jiang J., Sarwar N., Peston D., Kulinskaya E., Shousha S., Coombes R.C., Ali S. Phosphorylation of estrogen receptor-alpha at Ser(167) is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 2007, 13:5769-5776.
28. Joel P.B., Smith J., Sturgill T.W., Fisher T.L., Blenis J., Lannigan D.A. pp 90(rsk1) regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol. 1998, 18:1978-1984.
29. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21:60-65.
30. Klagsbrun M., D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996, 7:259-270.
31. Knowlton A.A., Lee A.R. Estrogen and the cardiovascular system. Pharmacol. Ther. 2012, 135:54-70.
32. Koh P.O. Nicotinamide attenuates the ischemic brain injury-induced decrease of Akt activation and Bad phosphorylation. Neurosci. Lett. 2011, 498:105-109.
33. Lannigan D.A. Estrogen receptor phosphorylation. Steroids 2003, 68:1-9.
34. Lee P., Goishi K., Davidson A.J., Mannix R., Zon L., Klagsbrun M. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10470-10475.
35. Lin A.H.Y., Li R.W.S., Ho E.Y.W., Leung G.P.H., Leung S.W.S., Vanhoutte P.M., Man R.Y.K. Differential ligand binding affinities of human estrogen receptor-alpha isoforms. PLoS One 2013, 8.
36. Ma L., Elliott S.N., Cirino G., Buret A., Ignarro L.J., Wallace J.L. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6470-6475.
37. Majewska I., Gendaszewska-Darmach E. Proangiogenic activity of plant extracts in accelerating wound healing - a new face of old phytomedicines. Acta Biochim. Pol. 2011, 58:449-460.
38. Masters S.C., Yang H., Datta S.R., Greenberg M.E., Fu H. 14-3-3 inhibits bad-induced cell death through interaction with serine-136. Mol. Pharmacol. 2001, 60:1325-1331.
39. Matori H., Umar S., Nadadur R.D., Sharma S., Partow-Navid R., Afkhami M., Amjedi M., Eghbali M. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension 2012, 60:425-430.
40. Mitsos S., Katsanos K., Koletsis E., Kagadis G.C., Anastasiou N., Diamantopoulos A., Karnabatidis D., Dougenis D. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis 2012, 15:1-22.
41. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
42. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30:2785-2791.
43. Motzer R.J., Hoosen S., Bello C.L., Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 2006, 15:553-561.
44. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 2010, 102:8-18.
45. Naumova E., Ubezio P., Garofalo A., Borsotti P., Cassis L., Riccardi E., Scanziani E., Eccles S.A., Bani M.R., Giavazzi R. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res. 2006, 12:1839-1849.
46. Notch E.G., Mayer G.D. Efficacy of pharmacological estrogen receptor antagonists in blocking activation of zebrafish estrogen receptors. Gen. Comp. Endocrinol. 2011, 173:183-189.
47. Ohi N., Nishikawa Y., Tokairin T., Yamamoto Y., Doi Y., Omori Y., Enomoto K. Maintenance of Bad phosphorylation prevents apoptosis of rat hepatic sinusoidal endothelial cells in vitro and in vivo. Am. J. Pathol. 2006, 168:1097-1106.
48. Pages G., Milanini J., Richard D.E., Berra E., Gothie E., Vinals F., Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann. N. Y. Acad. Sci. 2000, 902:187-200.
49. Pedram A., Razandi M., Aitkenhead M., Hughes C.C., Levin E.R. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem. 2002, 277:50768-50775.
50. Raja F.A., Hook J.M., Ledermann J.A. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat. Rev. 2012, 38:662-672.
51. Robert C., Soria J.C., Spatz A., Le Cesne A., Malka D., Pautier P., Wechsler J., Lhomme C., Escudier B., Boige V., Armand J.P., Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005, 6:491-500.
52. Rock E.P., Goodman V., Jiang J.X., Mahjoob K., Verbois S.L., Morse D., Dagher R., Justice R., Pazdur R. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12:107-113.
53. Sakao S., Tatsumi K. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiration 2011, 81:253-261.
54. Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., Kabbinavar F., Novotny W., Sarkar S., Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 2005, 91:173-180.
55. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5:519-524.
56. Smedlund K., Tano J.Y., Margiotta J., Vazquez G. Evidence for operation of nicotinic and muscarinic acetylcholine receptor-dependent survival pathways in human coronary artery endothelial cells. J. Cell. Biochem. 2011, 112:1978-1984.
57. Tang J.Y., Li S., Li Z.H., Zhang Z.J., Hu G., Cheang L.C., Alex D., Hoi M.P., Kwan Y.W., Chan S.W., Leung G.P., Lee S.M. Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One 2010, 5:e11822.
58. Taraseviciene-Stewart L., Kasahara Y., Alger L., Hirth P., McMahon G., Waltenberger J., Voelkel N.F., Tuder R.M. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001, 15:427-438.
59. Veronese M.L., Mosenkis A., Flaherty K.T., Gallagher M., Stevenson J.P., Townsend R.R., O'Dwyer P.J. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 2006, 24:1363-1369.
60. Vogel A.M., Weinstein B.M. Studying vascular development in the zebrafish. Trends Cardiovasc. Med. 2000, 10:352-360.
61. Wehland M., Bauer J., Infanger M., Grimm D. Target-based anti-angiogenic therapy in breast cancer. Curr. Pharm. Des. 2012, 18:4244-4257.
62. Westerfield M. The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio) 1995, 385. University of Oregon Press, Eugene, OR. 3rd edition.
63. Yaniv K., Isogai S., Castranova D., Dye L., Hitomi J., Weinstein B.M. Live imaging of lymphatic development in the zebrafish. Nat. Med. 2006, 12:711-716.
64. Young R.J., Reed M.W.R. Anti-angiogenic therapy: concept to clinic. Microcirculation 2012, 19:115-125.
65. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. Cell Physiol. 2001, 280:C1375-C1386.
66. Zhang X.L., Shu X.O., Gao Y.T., Yang G., Li Q., Li H.L., Jin F., Zheng W. Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. J. Nutr. 2003, 133:2874-2878.
67. Zhu Y.M., Wang C.C., Chen L., Qian L.B., Ma L.L., Yu J., Zhu M.H., Wen C.Y., Yu L.N., Yan M. Both PI3K/Akt and ERK1/2 pathways participate in the protection by dexmedetomidine against transient focal cerebral ischemia/reperfusion injury in rats. Brain Res. 2013, 1494:1-8.